Co-Authors
This is a "connection" page, showing publications co-authored by VICTOR PRIETO and ANTHONY LUCCI.
Connection Strength
0.282
-
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2023 Mar; 615(7953):E23.
Score: 0.055
-
Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2022 11; 611(7934):155-160.
Score: 0.054
-
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1941.
Score: 0.041
-
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1942.
Score: 0.041
-
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654.
Score: 0.041
-
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012 Dec 15; 18(24):6758-70.
Score: 0.027
-
Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res. 2011 Jul 15; 17(14):4882-91.
Score: 0.024